Publications
5803 Results
- Journal / Conference
- Int J Cancer, 145(12), 3244-3256
- Year
- 2019
- Research Committee(s)
- Prevention, Screening, and and Surveillance
The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies
- Journal / Conference
- JAMA Oncol. 2019 Aug 15:e191870
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
- Journal / Conference
- Pharmacogenetics and Genomics Feb;28(2):49-55
- Year
- 2018
- Research Committee(s)
- Breast
- PMID
- PMID29278617
- PMC
- PMC5824720
- Study Number(s)
- S0221
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
- Journal / Conference
- Biology of Blood and Marrow Transplantation Apr;24(4):700-707
- Year
- 2018
- Research Committee(s)
- Lymphoma
- PMID
- PMID29289757
- PMC
- PMC5965270
- Study Number(s)
- S0410
Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent hodgkin lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network phase II Trial (SWOG S0410/BMT CTN 0703)
- Journal / Conference
- Oncology 94(1):39-46
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID29040974
- PMC
- PMC5828967
- Study Number(s)
- CTSU/E2204
An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation (capecitabine and radiation) in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204)
- Journal / Conference
- Clinical Colorectal Cancer Mar;17(1):e121-e125; 2017 Oct 24 [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID29233486
- PMC
- PMCID6598683
- Study Number(s)
- S0713
SWOG S0713: A phase II study of cetuximab added to induction chemotherapy of oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer
- Journal / Conference
- Cancer Epidemiology Jun 21;55:117-122
- Year
- 2018
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID29936140
- PMC
- PMC6625804
- Study Number(s)
- S0000, SWOG-9217
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials
- Journal / Conference
- American Journal of Hematology Feb;93(2):E49-E52
- Year
- 2018
- Research Committee(s)
- Leukemia
- PMID
- PMID29164656
- PMC
- PMC5760282
- Study Number(s)
- S1612
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
- Journal / Conference
- Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]
- Year
- 2018
- Research Committee(s)
- Breast, Gastrointestinal, Genitourinary, Leukemia, Lung, Lymphoma, Myeloma, and Sarcoma
- PMID
- PMID29370458
- PMC
- PMC5963502
- Study Number(s)
- S0003, S0012, S0016, S0033, S0106, S0221, S0226, S0232, S0307, S0421, S0500, SWOG-8516 (INT-0067), SWOG-8600, SWOG-8809, SWOG-8814, SWOG-8894 (INT-0105) (EST-2889), SWOG-8897, SWOG-8905, SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195), SWOG-9031, SWOG-9125, SWOG-9210, SWOG-9240, SWOG-9304 (INT-0144), SWOG-9308, SWOG-9313, SWOG-9321, SWOG-9333, SWOG-9346, SWOG-9349, SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415), SWOG-9420, SWOG-9509, S9623, S9704, S9800, S9911, S9916
Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials
- Journal / Conference
- Journal of Clinical Oncology Feb 1;36(4):326-332
- Year
- 2018
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID29136387
- PMC
- PMC5805479
- Study Number(s)
- S1202